Alterations in Gut Microbiota and Metabolomic Profiles in Myasthenia Gravis: Findings from 16S rRNA Sequencing and Untargeted Metabolomics Analysis - Takeaways - MDSpire

Alterations in Gut Microbiota and Metabolomic Profiles in Myasthenia Gravis: Findings from 16S rRNA Sequencing and Untargeted Metabolomics Analysis

  • By

  • Yunan Shan

  • Wei Chen

  • Yanbin Li

  • April 23, 2026

  • 0 min

Share

  • 1

    Myasthenia gravis (MG) is an autoimmune disorder characterized by impaired neuromuscular transmission and muscle weakness.

  • 2

    MG patients exhibit significant gut dysbiosis, with reduced microbial diversity and specific taxa alterations compared to healthy controls.

  • 3

    Metabolomic analysis revealed 567 altered metabolites in MG patients, including decreased short-chain fatty acids and secondary bile acids.

  • 4

    Positive correlations were found between specific metabolites, such as lithocholic acid, and clinical severity in MG patients.

  • 5

    The study identifies potential microbial and metabolic biomarkers that may aid in the diagnosis and treatment of myasthenia gravis.

Original Source(s)

Alterations in Gut Microbiota and Metabolomic Profiles in Myasthenia Gravis: Findings from 16S rRNA Sequencing and Untargeted Metabolomics Analysis

  • by Yunan Shan, Wei Chen, Yanbin Li

  • April 23, 2026

Related Content

The Connection Between Periodontal Microbiota and Liver Disease Development: Insights into the Oral-Gut-Liver Axis

Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications

15x Spike: What Louisville Found

Scientists trace a PFAS surge 400 miles upstream.